8G3M image
Entry Detail
PDB ID:
8G3M
EMDB ID:
Title:
N2 neuraminidase of A/Tanzania/205/2010 H3N2 in complex with 3 FNI9 Fab molecules
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2023-02-08
Release Date:
2023-05-31
Method Details:
Experimental Method:
Resolution:
3.00 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:FNI9 Fab heavy chain
Chain IDs:B (auth: E), E (auth: A), I (auth: C)
Chain Length:231
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:FNI9 Fab light chain
Chain IDs:C (auth: F), F (auth: D), J (auth: I)
Chain Length:215
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Neuraminidase
Chain IDs:A (auth: G), D (auth: J), G (auth: K), H (auth: L)
Chain Length:492
Number of Molecules:4
Biological Source:Influenza A virus
Ligand Molecules
Primary Citation

Abstact

Rapidly evolving influenza A viruses (IAVs) and influenza B viruses (IBVs) are major causes of recurrent lower respiratory tract infections. Current influenza vaccines elicit antibodies predominantly to the highly variable head region of haemagglutinin and their effectiveness is limited by viral drift1 and suboptimal immune responses2. Here we describe a neuraminidase-targeting monoclonal antibody, FNI9, that potently inhibits the enzymatic activity of all group 1 and group 2 IAVs, as well as Victoria/2/87-like, Yamagata/16/88-like and ancestral IBVs. FNI9 broadly neutralizes seasonal IAVs and IBVs, including the immune-evading H3N2 strains bearing an N-glycan at position 245, and shows synergistic activity when combined with anti-haemagglutinin stem-directed antibodies. Structural analysis reveals that D107 in the FNI9 heavy chain complementarity-determinant region 3 mimics the interaction of the sialic acid carboxyl group with the three highly conserved arginine residues (R118, R292 and R371) of the neuraminidase catalytic site. FNI9 demonstrates potent prophylactic activity against lethal IAV and IBV infections in mice. The unprecedented breadth and potency of the FNI9 monoclonal antibody supports its development for the prevention of influenza illness by seasonal and pandemic viruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures